Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Payables (2021 - 2025)

Bioregenx (BRGX) has 5 years of Payables data on record, last reported at $1.5 million in Q3 2025.

  • For Q3 2025, Payables rose 9.96% year-over-year to $1.5 million; the TTM value through Sep 2025 reached $1.5 million, up 9.96%, while the annual FY2024 figure was $1.3 million, 112.31% up from the prior year.
  • Payables reached $1.5 million in Q3 2025 per BRGX's latest filing, down from $1.5 million in the prior quarter.
  • Across five years, Payables topped out at $1.5 million in Q2 2025 and bottomed at $11996.0 in Q4 2021.
  • Average Payables over 5 years is $767788.3, with a median of $952857.0 recorded in 2025.
  • Peak YoY movement for Payables: skyrocketed 3394.4% in 2024, then dropped 21.92% in 2025.
  • A 5-year view of Payables shows it stood at $11996.0 in 2021, then skyrocketed by 405.93% to $60691.0 in 2022, then soared by 917.24% to $617376.0 in 2023, then soared by 112.31% to $1.3 million in 2024, then grew by 14.78% to $1.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $1.5 million in Q3 2025, $1.5 million in Q2 2025, and $952857.0 in Q1 2025.